Sorafenib

Category: pharmacological

Aliases: Nexavar

Pharmacological Mechanism

Multi-kinase inhibitor — BRAF, VEGFR, PDGFR, c-Kit, FLT3, RET. Used for hepatocellular carcinoma + advanced renal cell carcinoma + radioactive-iodine refractory thyroid cancer. Hand-foot skin reaction + hypertension common.

Half-Life (t½)

PO: 30h

Dosing Guidelines

• PO: Typical 800 mg (Range: 200–800 mg)

Target Organ Systems

• cardiovascular
• endocrine
• digestive
• renal
• integumentary

Pathways It Modulates

• Ferroptosis (activator) — SLC7A11 inhibition → GSH depletion → ferroptosis
• MAPK / ERK (RAS-RAF-MEK-ERK) cascade (inhibitor) — RAF + multi-kinase (VEGFR/PDGFR)
• Necroptosis (inhibitor) — multi-kinase incl. RIPK1/3 (off-target); HCC, RCC
• PI3K / AKT signaling (inhibitor) — multi-kinase incl. RAF; partial PI3K context
• Tyrosine kinase inhibition (inhibitor) — VEGFR + PDGFR + RAF (multi-kinase)

Chemical Identifiers

• PubChem CID: 216239
• Formula: C21H16ClF3N4O3
• Molecular weight: 464.83 g/mol
• InChIKey: MLDQJTXFUGDVEO-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F

References

• PMID 18172272